|
|||||
|
|
An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal  Comments are closed  Finance, Intellectual property  biomedical, biotechnology, cancer, clinical trials, equity, Europe, investment, licensing, life sciences, pharmaceuticals, stem cells If you think that these are the best sectors for you to invest in right now, these following tips should help you get started. . . . → Read More: Investing In Science And Tech – What You Need To Know Here are some of the best ways to invest your money and hopefully make a tidy bit of profit, . . . → Read More: What Are Ways To Invest Your Money? 
A company spun-off from a university biochemistry lab is raising $30 million to fund discovery of treatments targeting RNA, genetic material instructing protein production in cells. . . . → Read More: RNA Therapeutics Company Raises $30M in First Venture Round One comment - (Comments are closed) Finance, New products biomedical, biotechnology, chemistry, entrepreneurs, equity, Europe, genomics, investment, life sciences, pharmaceuticals, physical sciences, university, venture capital 
A clinical trial is underway testing an inhaled therapy to quickly treat irregular heart rhythms, in cases where the problems occur occasionally and often resolve on their own. . . . → Read More: Trial Underway for Inhaled Heart Rhythm Drug, Developer Raises $42M Comments are closed Finance, New products biomedical, clinical trials, equity, heart disease, investment, life sciences, medical device, pharmaceuticals, venture capital 
A 5 year-old enterprise developing synthetic DNA for medical and agricultural chemicals, as well as data storage, is raising $70 million in its initial public stock offering. . . . → Read More: Synthetic DNA Company Raising $70 Million in IPO Comments are closed Finance biomedical, biotechnology, computer science, engineering, equity, genomics, investment, IPO, life sciences, semiconductors 
Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal Comments are closed Intellectual property, Joint ventures/collaborations biomedical, biotechnology, equity, genomics, investment, licensing, life sciences, pharmaceuticals 
A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding Comments are closed Finance, Intellectual property biomedical, biotechnology, cancer, chemistry, entrepreneurs, equity, Europe, investment, licensing, life sciences, pharmaceuticals, physical sciences, university, venture capital 
A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B One comment - (Comments are closed) Finance, Intellectual property biomedical, biotechnology, clinical trials, equity, genomics, investment, licensing, life sciences, pharmaceuticals 
A company developing a drug delivery technology to treat chronic sinus conditions is raising $29.5 million in its second venture financing round. . . . → Read More: $29.5M Funding Raised for Sinus Drug Delivery Company One comment - (Comments are closed) Finance, New products biomedical, chemistry, clinical trials, engineering, equity, investment, life sciences, materials science, medical device, pharmaceuticals, physical sciences, preclinical, university, venture capital |
||||
|
Copyright © 2019 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
